Hemispherx Expands Community and Physician Involvement

Philadelphia (PROTEXT) - Hemispherx Biopharma (Amex: HEB) said today that in response to approaches by physicians, the Aids Cooperative Treatment Groups (ACTG -- the major Federally funded nationwide organization of clinical experts in AIDS), and other patient advocacy groups, the company is evaluating proposals to support the formation of independent Community Advisory Boards for both the CFIDS and HIV disease categories. Community Advisory Boards (CAB) are independent groups formed to facilitate communications among physicians, patient advocates and drug development companies. CABs have provided important input to numerous pharmaceutical companies, including such multinational leaders as Merck, DuPont and Glaxo Wellcome. Some CABs receive initial funding from pharmaceutical companies to assist them in their early organizational stages. There is also Federal funding available for certain CABs that deal with severely debilitating or life threatening diseases, such as AIDS. The current movement to form CABs to facilitate physician and patient advocate communications with Hemispherx has gained momentum from recent articles in The New England Journal of Medicine that describe the emergence of multi-drug resistant strains of HIV and call for research and development into potential treatments with new mechanisms of action to combat these new viral strains for which presently available drugs may have limited utility. Hemispherx said that it would invite senior physicians from the Food and Drug Administration as well as internationally recognized AIDS clinical experts from ACTG to participate in all scientific and educational meetings with the CABs once their formation is complete. Hemispherx said that the prospective community members of the new CABs are highly experienced patient advocates who sit on Community Advisory Boards of other leading drug companies and have decades-long commitment to their respective service organizations including ACT UP. Hemispherx is a biopharmaceutical company specializing in new therapeutic approaches to HIV/AIDS, CFS (Chronic Fatigue Syndrome) and hepatitis B/C utilizing the immune system. It has offices in Philadelphia, Belgium and France and new drug development facilities in the Washington D.C. area. Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. ots Original Text Service: Hemispherx Biopharma, Inc. Internet: http://www.newsaktuell.de Contact: William A. Carter, M.D., CEO & Chairman of Hemispherx Biopharma, Inc. (USA) 215-988-0080; or William Jenks, Media (USA) 212-232-2222, Fax, (USA) 212-232-3232; or Sharon Will, Investor Relations (USA) 212-572-0762, Fax, (USA) 212-572-0764, for Hemispherx Biopharma, Inc. Web site: http://www.hemispherx.com Subscribers please note that material bearing the slug "PROTEXT" is not part of CTK's news service and is not to be published under the "CTK" slug. Protext is a commercial service providing distribution of press releases from clients, who are identified in the text of Protext reports and who bear full responsibility for their contents. PROTEXT